Let's review the charts and indicators.
Let's check out the charts and indicators of this biotech name.
Word is out that a Moderna experimental melanoma vaccine combined with Merck's Keytruda reduced the risk of relapse in people with skin cancer in a trail.
The charts of the biopharmaceutical company that focuses on neurodegenerative diseases indicate short-term caution but long-term promise.
A logistics giant and a small biotech have seen their shares struggle this year, but they are producing solid cash flow and look undervalued.
The stock bottomed in June/July and have worked higher.
Let's check the charts but be prepared for volatility.
Let's check the charts after a fundamental buy call.
After a cruel 2022, here are my views on this high-beta sector as we head into the new year.
We have two price targets.